• BioLife Solutions will hold a special shareholder meeting via remote communication on Oct. 5, 2026.
• Shareholders will vote on adopting the merger agreement under which Repligen would acquire BioLife.
• Deal terms call for USD 11.25 in cash plus 0.1442 shares of Repligen common stock per BioLife share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-061174), on September 09, 2026, and is solely responsible for the information contained therein.